Resistance to immune checkpoint inhibitors in NSCLC

In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance.

The post Resistance to immune checkpoint inhibitors in NSCLC appeared first on VJOncology.